NL-OMON48212已完成不适用
An open-label, mass balance study to investigate the absorption, distribution, metabolism and excretion of [14C]-OTL0038 after a single intravenous dose to healthy volunteers. - CS0326 On Target
On Target Laboratories, Inc0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Able to provide informed consent to participate in this study after reading
- •the participant information sheet and informed consent form and after having
- •the opportunity to discuss the study with the Investigator or designee.
- •2. Healthy and free from clinically significant illness or disease as
- •determined by medical history, physical examination, laboratory and other tests
- •at Screening.
- •3. Male Caucasian subjects, aged 18 to 60 years (inclusive) at Screening.
排除标准
- •1. Any finding of the medical examination (including blood pressure, pulse rate
- •and ECG) deviating from normal and of clinical relevance.
- •2. History or current clinically significant gastrointestinal, hepatic, renal,
- •respiratory, cardiovascular, metabolic, immunologic, hormonal disorders.
- •3. History of any major surgery within the last 4 weeks before Screening or any
- •bone fracture within the last 2 months before Screening.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the uptake, distribution, breakdown and excretion of a single dose of [14C]-etripamil administered with a nasal spray in healthy volunteersParoxysmal supraventricular tachycardia (PSVT)EUCTR2019-004979-39-NLMilestone Pharmaceuticals Inc.8
已完成
不适用
An open-label, mass balance study to investigate the absorption, metabolism and excretion of [14C]-EYP001a after a single oral dose to healthy male subjectsChronic liver diseases, HBV/NASHchronic hepatitis B virus (HBV) infection and non-alcoholic steatohepatitis (NASH).NL-OMON48170ENYO Pharma SA6
已完成
不适用
An open-label, mass balance study to investigate the absorption, metabolism and excretion of [14C]-PBI-4050 after a single 1200 mg oral dose to healthy male subjectsfibrosisinflammatory and fibrosis-related diseasesNL-OMON46181Prometic6
已完成
不适用
Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism And Excretion Of [14C]-Etripamil Nasal Spray After a Single Dose to Healthy Male Subjects.NL-OMON50057Milestone Pharmaceuticals Inc8
进行中（未招募）
1 期
OP-724-001 studyHealthy volunteersJPRN-jRCT2031230432Yuushi Haruyama6